NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.16 -2.83 (-3.68%) GOLD FUTURES
2,368.90 +23.10 (+0.98%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
54,189.02 +1,354.68 (+2.56%)
Rani Therapeutics Holdings, Inc. (RANI)
| Previous close | 5.5000 |
| Open | 5.2600 |
| Bid | 4.6100 x 100 |
| Ask | 4.7600 x 100 |
| Day's range | 4.5300 - 5.6400 |
| 52-week range | 1.8200 - 8.7500 |
| Volume | |
| Avg. volume | 150,103 |
| Market cap | 241.872M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2700 |
| Earnings date | 20 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.57 |
GlobeNewswireRani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include: H.C. Wainwright 2nd Annual BioConnect Investor ConferenceLocation: The Nasdaq Headquarters, New York CityDate: Monday, May 20th at 2:30pm E.TFormat
- GlobeNewswire
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC. Details of the presentatio
GuruFocus.comRani Therapeutics Q1 2024 Earnings: Financial Performance and Strategic Updates
Insights into Rani Therapeutics' First Quarter Results and Future Clinical Endeavors
